Bipolar Disorder Guidelines Reveal Gaps in Current Care

The Bipolar Treatment Playbook Has a Blind Spot

In 2018, a group of the world’s leading bipolar disorder researchers did something unusual. They published a 41 page set of treatment guidelines that, for the first time, ranked medications not just by how well they worked for one phase of the illness, but by how they performed across all phases: mania, depression, and long term stability.

The result, from the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the International Society for Bipolar Disorders (ISBD), is the most comprehensive clinical roadmap we have. It tells doctors exactly which drugs to reach for first for acute mania, which for bipolar depression, and which for maintenance. It covers children, pregnant women, the elderly. It addresses substance use, anxiety, and metabolic disorders.

But if you read it closely, the guidelines also reveal something uncomfortable. For all their detail, they expose how much we still do not know. The biggest gap? Bipolar II disorder, the milder but still devastating form that affects roughly 40 percent of people with bipolar spectrum illness, gets a fraction of the evidence. The authors (Yatham et al., 2018) are honest about this. They write that for bipolar II, “there is a paucity of high quality evidence to guide treatment decisions.” That is not a minor footnote. It is the central tension in the entire document.

What the Guidelines Actually Say

The Hierarchy of First Line Treatments

The CANMAT/ISBD team did something previous guidelines had not. They created a “hierarchical ranking” for first and second line treatments in bipolar I disorder. This means they looked at each medication’s effect on mania, depression, and maintenance, then assigned it a tier.

For acute mania, the first line options are a list of eight drugs: lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine. These can be used alone or in combination (Yatham et al., 2018). That is a lot of choices. But the hierarchy matters. Lithium, the oldest mood stabilizer, sits at the top. It works across all phases. Quetiapine, an atypical antipsychotic, is also top tier because it treats both mania and depression.

For bipolar I depression, the picture gets narrower. Only quetiapine and lurasidone (when combined with lithium or divalproex) are first line. Lithium and lamotrigine are also first line, but the authors note that lamotrigine is less effective for acute depression than for preventing relapse (Yatham et al., 2018). That is a crucial distinction for any doctor deciding what to prescribe in the moment.

For maintenance, the guidelines recommend continuing whatever worked in the acute phase, with one big exception: antidepressants. The authors found that antidepressants, while sometimes helpful short term, can cause mood switches into mania and do not reliably prevent relapse. So they are not first line for maintenance.

The Lithium Problem

Lithium is the oldest and most studied treatment for bipolar disorder. It reduces suicide risk, prevents both mania and depression, and has decades of evidence behind it. The guidelines rank it as first line for mania, depression, and maintenance.

But here is the problem: lithium is hard to use. It requires regular blood tests to monitor levels and kidney function. It can cause tremors, weight gain, and thyroid problems. Many patients stop taking it. The guidelines acknowledge this but do not solve it. They tell doctors to monitor, to educate, to adjust doses. They do not tell them how to get a patient who hates blood draws to stay on lithium for 30 years.

This is not a flaw in the guidelines. It is a flaw in the treatment itself. The authors (Yatham et al., 2018) are clear that “the choice of medication should be based on a shared decision making process that considers the patient’s preferences, prior treatment response, and tolerability.” But that is easier said than done when the best drug is also the most burdensome.

The Bipolar II Disparity

This is where the guidelines reveal their deepest gap. Bipolar II disorder is defined by hypomania (a less severe form of mania) and major depression. It is not just “bipolar lite.” People with bipolar II spend more time depressed than those with bipolar I, and they have higher rates of suicide attempts.

Yet the evidence base for treating bipolar II is thin. The authors (Yatham et al., 2018) write that “there are few randomized controlled trials specifically in bipolar II disorder.” So the guidelines largely extrapolate from bipolar I data. They recommend quetiapine as first line for bipolar II depression, and lithium or lamotrigine for maintenance. But they admit that the recommendations are based on “limited evidence” and “clinical consensus.”

This matters because bipolar II is often misdiagnosed as unipolar depression. Patients get antidepressants alone, which can trigger hypomania or rapid cycling. The guidelines try to address this by warning against antidepressant monotherapy. But without solid trials, doctors are left guessing.

How the Guidelines Were Built

The CANMAT/ISBD team reviewed all available randomized controlled trials, meta analyses, and open label studies up to 2017. They rated each treatment on a scale from 1 (highest quality evidence) to 4 (expert opinion). Then they added a second rating for “clinical support,” which accounts for safety, tolerability, and risk of switching into mania.

This two tier system is smart. A drug might have strong evidence from trials (Level 1) but a high risk of side effects, making it second line. Another might have weaker evidence (Level 2) but excellent tolerability, earning first line status.

The authors (Yatham et al., 2018) also created something new: a “treatment emergent affective switch” risk rating. This measures how likely a drug is to cause a switch from depression to mania. Antidepressants score high on this risk. Lithium and lamotrigine score low. For clinicians, this is a practical tool. For patients, it is a number that might change their life.

What the Guidelines Do Not Tell You

The Comorbidity Blind Spot

The guidelines have a section on comorbidities: substance use disorders, anxiety disorders, metabolic conditions. They recommend integrated care. They note that people with bipolar disorder have high rates of obesity, diabetes, and cardiovascular disease. They advise monitoring weight and metabolic markers.

But they do not tell doctors how to treat a patient who is manic, addicted to alcohol, and has a BMI of 38. They do not offer algorithms for simultaneous treatment. They say “consider” referral to addiction specialists. They say “monitor” metabolic parameters. These are not actionable steps. They are placeholders.

The authors (Yatham et al., 2018) are honest about this too. They write that “the evidence for managing comorbidities in bipolar disorder is limited.” That is the theme. The guidelines are a map of what we know, but the map has large white spaces.

The Pediatric and Geriatric Gaps

Children and adolescents with bipolar disorder are hard to study. The guidelines recommend lithium, quetiapine, and aripiprazole as first line for acute mania in youth. But they note that “the evidence base is smaller than in adults” (Yatham et al., 2018). For depression in youth, there are almost no trials. The authors recommend starting with psychotherapy and adding medication cautiously.

Older adults present a different challenge. They are more sensitive to side effects. They often take other medications. The guidelines recommend starting with low doses and monitoring carefully. But again, the evidence is sparse. Most trials exclude people over 65.

The Unanswered Question

The biggest question the guidelines raise is not about which drug to prescribe. It is about how to get patients to stay on treatment.

Bipolar disorder is a lifelong illness. Relapse rates are high. Up to 50 percent of patients stop taking medication within a year. The reasons are complex: side effects, denial of illness, desire for the “high” of mania, lack of insight. The guidelines mention the importance of psychoeducation and psychotherapy. They recommend cognitive behavioral therapy, family focused therapy, and interpersonal therapy as adjuncts to medication.

But they do not tell you how to convince a 22 year old who feels fine to keep taking lithium for the next 50 years. That is not a research gap. It is a human one.

What This Actually Means

• ▸If you have bipolar I disorder, the best first line treatment across all phases is lithium or quetiapine. These drugs have the strongest evidence for preventing both mania and depression. But they require careful monitoring and come with side effects that many patients find difficult.

• ▸If you have bipolar II disorder, the evidence is weaker. Quetiapine is the only drug with solid data for acute depression. For maintenance, lithium or lamotrigine are recommended, but the data are thin. You and your doctor will be making decisions based on clinical experience, not large trials.

• ▸Antidepressants are risky. They can trigger mania or rapid cycling, especially if used alone. The guidelines recommend using them only in combination with a mood stabilizer or antipsychotic, and only for short periods.

• ▸Comorbidities change everything. If you have bipolar disorder plus anxiety, substance use, or a metabolic condition, the guidelines do not have clear answers. You need a doctor who treats the whole picture, not just the mood episodes.

• ▸The guidelines are a starting point, not a final answer. They are based on the best evidence available in 2018. But the evidence has holes. The authors (Yatham et al., 2018) call for more research, especially in bipolar II, pediatric, and geriatric populations. Until that research arrives, treatment will remain an art as much as a science.